383 filings
Page 15 of 20
6-K
BNTX
BioNTech SE
5 Aug 20
Supply to be provided over the course of 2021, subject to Health Canada approval
8:33am
6-K
BNTX
BioNTech SE
5 Aug 20
BioNTech and Fosun Pharma Announce Start of Clinical Trial of mRNA-based COVID-19 Vaccine Candidate in China
6:41am
424B3
BNTX
BioNTech SE
31 Jul 20
Prospectus supplement
5:12pm
6-K
BNTX
BioNTech SE
31 Jul 20
BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab) Combination in Melanoma
8:44am
6-K
BNTX
BioNTech SE
31 Jul 20
Supply of 120 million doses to be provided in the first half of 2021, subject to regulatory approval
8:43am
6-K
BNTX
BioNTech SE
30 Jul 20
Current report (foreign)
6:42am
6-K
BNTX
BioNTech SE
30 Jul 20
Current report (foreign)
6:40am
424B3
BNTX
BioNTech SE
28 Jul 20
Prospectus supplement
9:01am
6-K
BNTX
BioNTech SE
28 Jul 20
Current report (foreign)
12:00am
6-K
BNTX
BioNTech SE
27 Jul 20
BioNTech Announces Closing of $512 Million Underwritten Offering
4:41pm
EFFECT
BNTX
BioNTech SE
27 Jul 20
Notice of effectiveness
12:16am
424B5
BNTX
BioNTech SE
24 Jul 20
Prospectus supplement for primary offering
5:05pm
F-1/A
BNTX
BioNTech SE
23 Jul 20
Registration statement (foreign) (amended)
5:15pm
6-K
BNTX
BioNTech SE
23 Jul 20
BioNTech Announces Pricing of Upsized Underwritten Offering and Terms of Rights Offering
6:07am
EFFECT
BNTX
BioNTech SE
23 Jul 20
Notice of effectiveness
12:15am
F-1MEF
BNTX
BioNTech SE
22 Jul 20
Registration statement to add securities to prior F-1 registration
8:08pm
6-K
BNTX
BioNTech SE
22 Jul 20
Pfizer and BioNTech Announce an Agreement with U. S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
5:08pm
F-1/A
BNTX
BioNTech SE
22 Jul 20
Registration statement (foreign) (amended)
7:54am
FWP
BNTX
BioNTech SE
22 Jul 20
Free writing prospectus
12:00am
FWP
BNTX
BioNTech SE
22 Jul 20
Free writing prospectus
12:00am